Affiliation:
1. Epidemiology Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
2. Laboratoire de Biométrie et de Biologie Évolutive, Université de Lyon, Lyon, France
3. Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Abstract
ABSTRACT
The rising incidence of
Clostridium difficile
infection (CDI) could be reduced by lowering exposure to high-risk antibiotics. The objective of this study was to determine the association between antibiotic class and the risk of CDI in the community setting. The EMBASE and PubMed databases were queried without restriction to time period or language. Comparative observational studies and randomized controlled trials (RCTs) considering the impact of exposure to antibiotics on CDI risk among nonhospitalized populations were considered. We estimated pooled odds ratios (OR) for antibiotic classes using random-effect meta-analysis. Our search criteria identified 465 articles, of which 7 met inclusion criteria; all were observational studies. Five studies considered antibiotic risk relative to no antibiotic exposure: clindamycin (OR = 16.80; 95% confidence interval [95% CI], 7.48 to 37.76), fluoroquinolones (OR = 5.50; 95% CI, 4.26 to 7.11), and cephalosporins, monobactams, and carbapenems (CMCs) (OR = 5.68; 95% CI, 2.12 to 15.23) had the largest effects, while macrolides (OR = 2.65; 95% CI, 1.92 to 3.64), sulfonamides and trimethoprim (OR = 1.81; 95% CI, 1.34 to 2.43), and penicillins (OR = 2.71; 95% CI, 1.75 to 4.21) had lower associations with CDI. We noted no effect of tetracyclines on CDI risk (OR = 0.92; 95% CI, 0.61 to 1.40). In the community setting, there is substantial variation in the risk of CDI associated with different antimicrobial classes. Avoidance of high-risk antibiotics (such as clindamycin, CMCs, and fluoroquinolones) in favor of lower-risk antibiotics (such as penicillins, macrolides, and tetracyclines) may help reduce the incidence of CDI.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference36 articles.
1. KwongJ CrowcroftN CampitelliM DanemanN DeeksS ManuelD. 2010. Ontario Burden of Infectious Disease Study (ONBOIDS): an OAHPP/ICES report. Ontario Agency for Health Protection and Promotion and Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
2. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C. difficile-associated disease;Dubberke ER;Arch. Intern. Med.,2007
3. Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005;Centers for Disease Control and Prevention;Morb. Mortal. Wkly. Rep.,2005
4. Clinical and microbiological characteristics of community-onset Clostridium difficile infection in The Netherlands;Bauer MP;Clin. Microbiol. Infect.,2009
5. Community Clostridium difficile;Rangaiah J;BMJ,2009
Cited by
482 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献